Top Wall Street Analysts Share Insights on 3 High-Dividend Yield Health Care Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy MRK?
Source: Benzinga
Investor Interest in Dividend Stocks: In uncertain market conditions, investors are increasingly looking at dividend-yielding stocks, which typically have strong free cash flows and offer high dividend payouts.
DENTSPLY SIRONA Inc (XRAY): The company has a dividend yield of 4.98%. Analyst Kevin Caliendo from UBS maintains a Buy rating with a price target of $23, while Jonathan Block from Stifel holds a Hold rating with a reduced price target of $17.
Merck & Co Inc (MRK): With a dividend yield of 3.74%, Citigroup's Geoff Meacham reinstated a Neutral rating and raised the price target to $95, while Wells Fargo's Mohit Bansal maintained an Equal-Weight rating with a lowered target of $90.
Viatris Inc (VTRS): The company has a dividend yield of 4.67%. Analyst David Amsellem from Piper Sandler reiterated a Neutral rating with a price target cut to $10, while Jason Gerberry from B of A Securities maintained an Underperform rating with a target of $10.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.460
Low
95.00
Averages
119.53
High
139.00
Current: 115.460
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EUROPEAN COMMISSION GIVES GREEN LIGHT TO MERCK'S ENFLONSIA™ (CLESROVIMAB) FOR INFANT RSV LOWER RESPIRATORY TRACT DISEASE PREVENTION IN FIRST RSV SEASON
Approval of Vaccine: The European Commission has approved Merck's Senflonasia™ (Clesrovimab) for the prevention of respiratory syncytial virus (RSV) in infants during their first RSV season.
Target Population: The vaccine is specifically aimed at lowering the risk of respiratory tract disease caused by RSV in infants, addressing a significant health concern in this vulnerable age group.
See More
Trump Nominates New CDC Director Amid Turmoil
- Leadership Changes: Trump has nominated Erica Schwartz to serve as the CDC director, concluding a months-long search, with her confirmation pending Senate approval, which could significantly influence the agency's future direction.
- Interim Leadership Issues: Prior to Schwartz's nomination, Jay Bhattacharya served as acting director, but his term expired last month, highlighting instability within the CDC as the Vacancies Act limits interim officials to 210 days.
- Vaccine Policy Controversy: Amid leadership upheaval, declining morale, and significant staff turnover, the CDC faces major changes to U.S. vaccine policy, particularly after a judge blocked efforts to reduce the number of recommended childhood vaccinations, exacerbating public trust issues.
- Declining Public Trust: A February poll from KFF indicates a significant drop in public trust in federal health agencies during Kennedy's tenure as Secretary of Health and Human Services, which may hinder the CDC's effectiveness and implementation of future public health policies.
See More
Analysis and Recommendations on Stocks Near Market Highs
- Allient Stock Risks: Allient (NASDAQ:ALNT) has experienced a 2.1% annual sales decline over the past two years, indicating its products have struggled to meet market demand, leading to a concerning 2.7% annual drop in earnings per share, with the current stock price at $73 and a forward P/E of 26.1, suggesting caution for investors.
- SLB Stock Warning: SLB (NYSE:SLB) has seen a 1.2% annual sales decline over the past decade, reflecting unfavorable market trends, and despite a gross margin of 21.5%, high production costs and an unfavorable asset base present challenges, with the current stock price at $52.19 and a forward P/E of 19.3, prompting investors to reassess their holdings.
- Merck Stock Advantages: Merck (NYSE:MRK) boasts a substantial revenue base of $65.09 billion, providing competitive advantages in a complex regulatory environment, with a 30.8 percentage point improvement in adjusted operating margin over the past two years, indicating efficient scaling, and a current stock price of $120.67 with a forward P/E of 23.8, making it a worthy consideration for investors.
- Market Trend Analysis: While several stocks are trading near their 52-week highs, investors should remain cautious of short-term trends, and selecting fundamentally strong stocks like Merck may yield better returns in the future.
See More
Rapid Growth of GLP-1 Drug Market
- Market Surge: According to Markets and Markets, the GLP-1 agonist market grew from $53.74 billion in 2024 to $64.42 billion in 2025, with projections reaching $170.75 billion by 2033, indicating a robust demand for obesity and diabetes treatments.
- New Drug Approval: In 2025, Novo Nordisk's Wegovy received FDA approval as the first oral GLP-1 weight-loss medication, marking a significant breakthrough in treatment options, particularly for those with trypanophobia, which is expected to further drive market demand.
- Top-Selling Drugs: In 2025, Mounjaro led the GLP-1 drug market with $22.97 billion in sales, followed by Ozempic and Zepbound with $20 billion and $13.54 billion, respectively, showcasing the strong appeal of GLP-1 therapies globally.
- Patent Protection and Competition: While Ozempic and Wegovy are protected by patents in the U.S. until around 2032, generics have already launched in India and are expected in China, intensifying market competition and potentially impacting the market share of original branded drugs.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
EUROPEAN COMMISSION GIVES GREEN LIGHT TO MERCK'S ENFLONSIA™ (CLESROVIMAB) FOR INFANT RSV LOWER RESPIRATORY TRACT DISEASE PREVENTION IN FIRST RSV SEASON
Approval of Vaccine: The European Commission has approved Merck's Senflonasia™ (Clesrovimab) for the prevention of respiratory syncytial virus (RSV) in infants during their first RSV season.
Target Population: The vaccine is specifically aimed at lowering the risk of respiratory tract disease caused by RSV in infants, addressing a significant health concern in this vulnerable age group.
See More
Trump Nominates New CDC Director Amid Turmoil
- Leadership Changes: Trump has nominated Erica Schwartz to serve as the CDC director, concluding a months-long search, with her confirmation pending Senate approval, which could significantly influence the agency's future direction.
- Interim Leadership Issues: Prior to Schwartz's nomination, Jay Bhattacharya served as acting director, but his term expired last month, highlighting instability within the CDC as the Vacancies Act limits interim officials to 210 days.
- Vaccine Policy Controversy: Amid leadership upheaval, declining morale, and significant staff turnover, the CDC faces major changes to U.S. vaccine policy, particularly after a judge blocked efforts to reduce the number of recommended childhood vaccinations, exacerbating public trust issues.
- Declining Public Trust: A February poll from KFF indicates a significant drop in public trust in federal health agencies during Kennedy's tenure as Secretary of Health and Human Services, which may hinder the CDC's effectiveness and implementation of future public health policies.
See More
Analysis and Recommendations on Stocks Near Market Highs
- Allient Stock Risks: Allient (NASDAQ:ALNT) has experienced a 2.1% annual sales decline over the past two years, indicating its products have struggled to meet market demand, leading to a concerning 2.7% annual drop in earnings per share, with the current stock price at $73 and a forward P/E of 26.1, suggesting caution for investors.
- SLB Stock Warning: SLB (NYSE:SLB) has seen a 1.2% annual sales decline over the past decade, reflecting unfavorable market trends, and despite a gross margin of 21.5%, high production costs and an unfavorable asset base present challenges, with the current stock price at $52.19 and a forward P/E of 19.3, prompting investors to reassess their holdings.
- Merck Stock Advantages: Merck (NYSE:MRK) boasts a substantial revenue base of $65.09 billion, providing competitive advantages in a complex regulatory environment, with a 30.8 percentage point improvement in adjusted operating margin over the past two years, indicating efficient scaling, and a current stock price of $120.67 with a forward P/E of 23.8, making it a worthy consideration for investors.
- Market Trend Analysis: While several stocks are trading near their 52-week highs, investors should remain cautious of short-term trends, and selecting fundamentally strong stocks like Merck may yield better returns in the future.
See More
Rapid Growth of GLP-1 Drug Market
- Market Surge: According to Markets and Markets, the GLP-1 agonist market grew from $53.74 billion in 2024 to $64.42 billion in 2025, with projections reaching $170.75 billion by 2033, indicating a robust demand for obesity and diabetes treatments.
- New Drug Approval: In 2025, Novo Nordisk's Wegovy received FDA approval as the first oral GLP-1 weight-loss medication, marking a significant breakthrough in treatment options, particularly for those with trypanophobia, which is expected to further drive market demand.
- Top-Selling Drugs: In 2025, Mounjaro led the GLP-1 drug market with $22.97 billion in sales, followed by Ozempic and Zepbound with $20 billion and $13.54 billion, respectively, showcasing the strong appeal of GLP-1 therapies globally.
- Patent Protection and Competition: While Ozempic and Wegovy are protected by patents in the U.S. until around 2032, generics have already launched in India and are expected in China, intensifying market competition and potentially impacting the market share of original branded drugs.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
